Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

DIABETES

Two drugs are better than one to start T2DM therapy

Early and intensive glycaemic control protects patients with type 2 diabetes mellitus (T2DM) from the development of late cardiovascular complications. The authors of the VERIFY trial now show that a more durable attainment of HbA1cā€‰<7% is observed by adding vildagliptin to metformin as starting therapy in newly diagnosed patients with T2DM.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Proposal for merging the glucocentric and the cardiocentric view of T2DM treatment.

References

  1. [No authors listed.] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837ā€“853 (1998).

  2. Holman, R. R. et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577ā€“1589 (2008).

    ArticleĀ  CASĀ  Google ScholarĀ 

  3. Laiteerapong, N. et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care 42, 416ā€“426 (2019).

    ArticleĀ  CASĀ  Google ScholarĀ 

  4. Brown, J. B., Conner, C. & Nichols, G. A. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care 33, 501ā€“506 (2010).

    ArticleĀ  CASĀ  Google ScholarĀ 

  5. Phung, O. J. et al. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes. Metab. 16, 410ā€“417 (2014).

    ArticleĀ  CASĀ  Google ScholarĀ 

  6. Matthews, D. R. et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet 394, 1519ā€“1529 (2019).

    ArticleĀ  CASĀ  Google ScholarĀ 

  7. Schnell, O. et al. Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc. Diabetol. 18, 30 (2019).

    ArticleĀ  Google ScholarĀ 

  8. Davies, M. J. et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41, 2669ā€“2701 (2018).

    ArticleĀ  Google ScholarĀ 

  9. Cosentino, F. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. https://doi.org/10.1093/eurheartj/ehz486 (2019).

  10. Abdul-Ghani, M. & DeFronzo, R. A. Is it time to change the type 2 diabetes treatment paradigm? Yes! GLP-1 RAs should replace metformin in the type 2 diabetes algorithm. Diabetes Care 40, 1121ā€“1127 (2017).

    ArticleĀ  CASĀ  Google ScholarĀ 

Download references

Acknowledgements

The authors thank the Italian Ministry of Health (Ricerca Corrente), who supported part of this work.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Antonio Ceriello.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Prattichizzo, F., La Sala, L. & Ceriello, A. Two drugs are better than one to start T2DM therapy. Nat Rev Endocrinol 16, 15ā€“16 (2020). https://doi.org/10.1038/s41574-019-0294-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41574-019-0294-3

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter ā€” what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing